Tong Ren Tang Technologies (HKG:1666) recorded a 24% decline in attributable profit in 2025 to 396.3 million yuan from 521.8 million yuan a year prior, according to a March 27 Hong Kong bourse filing.
Shares of the traditional Chinese medicine manufacturer were down nearly 3% in Monday afternoon trading.
Earnings per share were 0.31 yuan in the year, down from 0.41 yuan in the prior-year period.
Revenue slipped 11% to 6.48 billion yuan from 7.26 billion yuan previously.
The firm proposed a final dividend of 0.18 yuan per share for the year, payable by Aug. 11, subject to shareholder approval.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.